Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228145 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy Study for Children With CLN5 Batten Disease
A Phase 1 study of Neuronal Ceroid Lipofuscinosis CLN5, sponsored by Neurogene.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT05228145 is a Phase 1 study of Neuronal Ceroid Lipofuscinosis CLN5 that is active but no longer recruiting, run by Neurogene. The registered enrollment target is 6 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05228145, a Phase 1 study of Neuronal Ceroid Lipofuscinosis CLN5, is active but no longer recruiting, sponsored by Neurogene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, non-randomized, open-label, dose escalation study of a single administration of gene therapy in children who are 3 to 9 years old with Neuronal Ceroid Lipofuscinosis (Batten) Subtype 5 (CLN5) disease.
Conditions Studied
Interventions
- GENETIC NGN-101
Study Locations (2)
New York
- University of Rochester - Rochester
Other
- Great Ormond Street Hospital for Children - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05228145
The ClinicalTrials.gov registry entry for NCT05228145 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuronal Ceroid Lipofuscinosis CLN5 appearing as the primary indexed condition, and to 1 intervention - of which NGN-101 is the first listed.
NCT05228145 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT05228145 about?
NCT05228145 is a clinical study titled "Gene Therapy Study for Children With CLN5 Batten Disease". This is a prospective, non-randomized, open-label, dose escalation study of a single administration of gene therapy in children who are 3 to 9 years old with Neuronal Ceroid Lipofuscinosis (Batten) Subtype 5 (CLN5) disease.
What is the current status of trial NCT05228145?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-01-31. Estimated completion is 2028-11.
What conditions does trial NCT05228145 study?
This clinical trial studies the following conditions: Neuronal Ceroid Lipofuscinosis CLN5.
What interventions are being tested in trial NCT05228145?
The interventions under investigation include: NGN-101 (GENETIC).
Who is sponsoring clinical trial NCT05228145?
This trial is sponsored by Neurogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05228145 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuronal Ceroid Lipofuscinosis CLN5
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.